Hillstream Biopharma Expanded Its Collaboration With Minotaur Therapeutics And Its License Agreement With OmniAb To Advance Next-generation Targeted Knob Biologics (Picobodies) Against HER3 And A New Undisclosed Oncology Target

7/20/23 8:10:45 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $HILS alert in real time by email

Get the next $HILS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$HILS

Date	Price Target	Rating	Analyst

More analyst ratings

$HILS
Press Releases

Fastest customizable press release news feed in the world

Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.
Expects to launch and complete a Phase 1 trial in Q4 2023Tharimmune to begin trading under new ticker, THAR, on Monday September 25, 2023BRIDGEWATER, NJ / ACCESSWIRE / September 22, 2023 / Hillstream BioPharma Inc., (NASDAQ:HILS), a biotechnology company developing innovative therapeutic candidates in rare immune, inflammatory and oncologic diseases announced a corporate name change to Tharimmune, Inc., ("Tharimmune"). The corporate name change is based on the Greek word "thárros", translated to mean courage and reflects the transformation of the Company into a patient-focused, clinical development organization. The Company's common stock will trade on The Nasdaq Capital Market under a new t
9/22/23 8:30:00 AM ET
$HILS
Biotechnology: Pharmaceutical Preparations
Health Care
Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis
Anticipate completion of Phase 1 & Phase 2 clinical trials in chronic pruritis over the next approximately 12 months Seeking first approval in an orphan disease, PBC, for the treatment of moderate to severe chronic pruritis in which more than 70% of patients suffer from chronic pruritis BRIDGEWATER, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancer announces an exclusive option agreement to acquire a clinical stage asset, AV104, with a recently approved IND. AV104 has a dual mechanism of action by affecting multiple rec
9/11/23 11:51:49 AM ET
$HILS
Biotechnology: Pharmaceutical Preparations
Health Care
Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13
Management will present and hold virtual 1-on-1 meetings with institutional investors and analysts BRIDGEWATER, N.J., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers with immuno-oncology targeted novel biologics, today announced that it will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference, being held in person and virtually from September 11-13, 2023. Event: H.C. Wainwright Presentation On-DemandDate: September 11th, 2023Time: 7:00am ETRegistration: Link *Please note that Company presentation
9/8/23 2:30:00 PM ET
$HILS
Biotechnology: Pharmaceutical Preparations
Health Care

$HILS
Market Insights

Live Market Insights

Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset And Announces Corporate Name Change To Tharimmune; Stock To Trade On Nasdaq Under "THAR" Effective Sept. 25
Expects to launch and complete a Phase 1 trial in Q4 2023Tharimmune to begin trading under new ticker, THAR, on Monday September 25, 2023
9/22/23 9:06:14 AM ET
$HILS
Biotechnology: Pharmaceutical Preparations
Health Care
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Avalo Therapeutics (NASDAQ:AVTX) shares rose 38.4% to $0.14 during Friday's pre-market session. The company's market cap stands at $2.8 million. Synaptogenix (NASDAQ:SNPX) stock rose 13.69% to $0.32. The market value of their outstanding shares is at $3.2 million. Hillstream BioPharma (NASDAQ:HILS) stock increased by 13.68% to $0.26. The market value of their outstanding shares is at $4.4 million. SeaStar Medical Holding (NASDAQ:ICU) shares moved upwards by 12.9% to $0.21. The company's market cap stands at $4.0 million. Alpha Teknova (NASDAQ:TKNO) shares increased by 12.23% to $2.11. The market value of their outstanding shares is at $85.9 million. Agile Therapeutics (NASDAQ:A
9/22/23 9:06:01 AM ET
$AFIB
$AGRX
$AMTI
$AVTX
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) stock increased by 63.8% to $26.16 during Monday's regular session. As of 13:30 EST, Crinetics Pharmaceuticals's stock is trading at a volume of 21.3 million, which is 4355.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.4 billion. Novo Integrated Sciences (NASDAQ:NVOS) shares increased by 42.8% to $0.38. As of 13:30 EST, this security is trading at a volume of 98.4 million shares, making up 278.6% of its average full-day volume over the last 100 days. The company's market cap stands at $60.2 million. Akanda (NASDAQ:AKAN) stock rose 30.3% to $0.86. Trading volume for Akanda's st
9/11/23 1:31:13 PM ET
$AKAN
$AXLA
$CRNX
$HILS
Medicinal Chemicals and Botanical Products
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations

Hillstream Biopharma Expanded Its Collaboration With Minotaur Therapeutics And Its License Agreement With OmniAb To Advance Next-generation Targeted Knob Biologics (Picobodies) Against HER3 And A New Undisclosed Oncology Target

Chat with this insight

Recent Analyst Ratings for
$HILS

$HILS
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Milby Randy bought $14,587 worth of shares (29,000 units at $0.50), increasing direct ownership by 23% to 156,517 units (SEC Form 4)

Milby Randy bought $10,000 worth of shares (10,000 units at $1.00), increasing direct ownership by 9% to 127,517 units (SEC Form 4)

SEC Form 4 filed by Bui Lynne A.

$HILS
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Milby Randy bought $14,587 worth of shares (29,000 units at $0.50), increasing direct ownership by 23% to 156,517 units (SEC Form 4)

Milby Randy bought $10,000 worth of shares (10,000 units at $1.00), increasing direct ownership by 9% to 127,517 units (SEC Form 4)

$HILS
Press Releases

Fastest customizable press release news feed in the world

Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.

Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis

Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13

$HILS
SEC Filings

Hillstream BioPharma Inc. filed SEC Form 8-K: Other Events

Hillstream BioPharma Inc. filed SEC Form 8-K: Other Events

Hillstream BioPharma Inc. filed SEC Form 8-K: Other Events (Amendment)

$HILS
Market Insights

Live Market Insights

Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset And Announces Corporate Name Change To Tharimmune; Stock To Trade On Nasdaq Under "THAR" Effective Sept. 25

12 Health Care Stocks Moving In Friday's Pre-Market Session

12 Health Care Stocks Moving In Monday's Intraday Session

$HILS
Leadership Updates

Live Leadership Updates

$HILS
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics

Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson

SEC Form SC 13G/A filed by Hillstream BioPharma Inc. (Amendment)

SEC Form SC 13G filed by Hillstream BioPharma Inc.

Hillstream Biopharma Expanded Its Collaboration With Minotaur Therapeutics And Its License Agreement With OmniAb To Advance Next-generation Targeted Knob Biologics (Picobodies) Against HER3 And A New Undisclosed Oncology Target

Chat with this insight

Recent Analyst Ratings for $HILS

$HILS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Milby Randy bought $14,587 worth of shares (29,000 units at $0.50), increasing direct ownership by 23% to 156,517 units (SEC Form 4)

Milby Randy bought $10,000 worth of shares (10,000 units at $1.00), increasing direct ownership by 9% to 127,517 units (SEC Form 4)

SEC Form 4 filed by Bui Lynne A.

$HILS Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Milby Randy bought $14,587 worth of shares (29,000 units at $0.50), increasing direct ownership by 23% to 156,517 units (SEC Form 4)

Milby Randy bought $10,000 worth of shares (10,000 units at $1.00), increasing direct ownership by 9% to 127,517 units (SEC Form 4)

$HILS Press Releases

Fastest customizable press release news feed in the world

Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.

Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis

Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13

$HILS SEC Filings

Hillstream BioPharma Inc. filed SEC Form 8-K: Other Events

Hillstream BioPharma Inc. filed SEC Form 8-K: Other Events

Hillstream BioPharma Inc. filed SEC Form 8-K: Other Events (Amendment)

$HILS Market Insights

Live Market Insights

Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset And Announces Corporate Name Change To Tharimmune; Stock To Trade On Nasdaq Under "THAR" Effective Sept. 25

12 Health Care Stocks Moving In Friday's Pre-Market Session

12 Health Care Stocks Moving In Monday's Intraday Session

$HILS Leadership Updates

Live Leadership Updates

$HILS Large Ownership Changes

This live feed shows all institutional transactions in real time.

Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics

Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson

SEC Form SC 13G/A filed by Hillstream BioPharma Inc. (Amendment)

SEC Form SC 13G filed by Hillstream BioPharma Inc.

Recent Analyst Ratings for
$HILS

$HILS
Insider Trading

$HILS
Insider Purchases

$HILS
Press Releases

$HILS
SEC Filings

$HILS
Market Insights

$HILS
Leadership Updates

$HILS
Large Ownership Changes